XOMA Co. (NASDAQ:XOMA) Shares Sold by TLS Advisors LLC

TLS Advisors LLC lowered its position in XOMA Co. (NASDAQ:XOMA) by 0.8% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 118,844 shares of the biotechnology company’s stock after selling 900 shares during the period. XOMA comprises approximately 7.1% of TLS Advisors LLC’s holdings, making the stock its 6th largest position. TLS Advisors LLC’s holdings in XOMA were worth $3,123,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of XOMA. JPMorgan Chase & Co. increased its position in XOMA by 238.9% in the 4th quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock valued at $318,000 after acquiring an additional 8,522 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of XOMA by 5.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 23,113 shares of the biotechnology company’s stock valued at $607,000 after purchasing an additional 1,276 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of XOMA during the fourth quarter worth $206,000. New York State Common Retirement Fund grew its position in XOMA by 51.2% in the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 800 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in XOMA by 18.1% in the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock valued at $291,000 after buying an additional 1,699 shares during the period. 95.92% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CIO Bradley Sitko purchased 4,134 shares of the company’s stock in a transaction on Friday, March 21st. The shares were bought at an average cost of $23.89 per share, with a total value of $98,761.26. Following the transaction, the executive now directly owns 10,484 shares of the company’s stock, valued at $250,462.76. This represents a 65.10 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 4,747 shares of company stock worth $114,544 over the last ninety days. 7.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

XOMA has been the topic of a number of recent analyst reports. StockNews.com upgraded shares of XOMA from a “sell” rating to a “hold” rating in a research note on Friday, March 21st. HC Wainwright reiterated a “buy” rating and set a $104.00 target price on shares of XOMA in a research report on Friday.

XOMA Stock Performance

Shares of XOMA opened at $20.33 on Friday. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA Co. has a 52-week low of $19.92 and a 52-week high of $35.00. The company has a 50-day simple moving average of $23.76 and a 200-day simple moving average of $26.90. The company has a market capitalization of $243.53 million, a PE ratio of -5.84 and a beta of 1.00.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). The company had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. Equities research analysts predict that XOMA Co. will post -1.41 earnings per share for the current fiscal year.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.